Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Antibe Therapeutics Inc. has undergone significant changes, with the appointment of FTI Consulting Canada Inc. as receiver following the termination of its CCAA proceedings, and the resignation of five board members. Additionally, the company’s common shares are set to be delisted from the TSX on May 24, 2024.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.
